Losing weight can often seem like an uphill battle, especially if you're trying to get rid of stubborn abdominal fat that ...

Insulet’s stock price target has recently been raised, with the fair value estimate increasing from $366 to $378 following the company's Investor Day and updated outlook. This change reflects ...

Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show a benefit over a placebo against Alzheimer's disease.

Last week, Novo Nordisk NVO announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic ...

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global ...